Forbes Medi-Tech has an answer for folks wanting to lower their cholesterol by changing their diet. The firm makes Reducol, a dietary supplement ingredient that reduces LDL, the "bad" cholesterol associated with increased risk of heart disease. It sells the ingredient to food and nutritionals companies that incorporate it into their products. Pharmavite uses Reducol in its Cholest-Off supplement, and foodmakers in Europe use it in items such as yogurt, milk, and bread. Until 2008 Forbes Medi-Tech also had a drug development operation, which was testing pharmaceutical candidates to treat high cholesterol and metabolic conditions; however, it has divested those operations to focus on its Reducol business.

GlaxoSmithKline Biologicals s.a. company was founded in 1945 and is based in Rixensart, Belgium. Glaxosmithkline Biologicals S.A. operates as a subsidiary of GlaxoSmithKline plc. Glaxosmithkline Biologicals S.A. engages in the research, development, manufacture, and supply of vaccines. Its vaccination products are used to tackle various diseases, such as rabies, diphtheria, tetanus, and yellow fever, as well as polio, measles, mumps, and rubella and hepatitis B. Glaxosmithkline Biologicals S.A. was formerly known as SmithKline Beecham Biologicals S.A. and changed its name to GlaxoSmithKline Biologicals S.A. in 2000.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935; the founder's sons now head the company. Cipla is a market-leading medicine maker in India. The company has roughly 5,500 pharmaceutical products. Some are sold domestically, while the rest reach international markets in some 170 countries. It offers prescription drugs for all kinds of ailments -- arthritis, cancer, depression -- as well as over-the-counter drugs for colds, oral hygiene, and skin care. Cipla leads the domestic retail pharmaceutical market. The firm also makes bulk drugs, agrochemicals, and animal products. It has eight manufacturing plants located throughout the country.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Allergan Limited company is the UK subsidiary of US pharmaceutical company Allergan. Like its American parent, the company is focused on eye and skin care medications and neurological disorder treatments. Products available in the UK include eye twitching and wrinkle removing drug Botox, glaucoma treatment Lumigan, steroidal eye medication Pred Forte, allergy drug Relestat, and psoriasis treatment Zorac. The company is also the headquarters of its parent's European research and development operations; its efforts target areas including retinal disease, skin disorders, and pain.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

Isagenix International company develops and manufactures a range of health and wellness products from nutritional and dietary supplements to skin care products and systems. Isagenix's line of "Nutritional Cleansing" products help improve health by accelerating the removal of impurities from the body and by replacing the impurities with nutrients to revive health. The company also offers dietary supplements to help customers lose weight and increase energy. A network marketing enterprise, Isagenix provides the products and sales support services to its international network of associates, relying on its associates to sell the products and recruit new associates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.